President and Chief Executive Officer
Derek was named President and Chief Executive Officer of PlateletBio in March 2022. Prior to that, he was Chief Operating Officer leading the Manufacturing and Technical Operations organization as well as additional strategic and operational responsibilities across the company. Before joining PlateletBio, Derek was Chief Technology and Manufacturing Officer at bluebird bio, where he was a member of the leadership team and oversaw pharmaceutical sciences and quality functions. Prior to bluebird, he was Senior Vice President, CMC at Evelo Biosciences, and, prior to that, he held senior leadership roles of increasing responsibility in process development and manufacturing at Alexion Pharmaceuticals. He started his career with Merck & Co, Inc. in Vaccine Technology and Engineering. Derek is a member of the manufacturing advisory board of Jasper Therapeutics and on the Advisory Committee of the BioInnovation Group. He earned a Ph.D. in Chemical Engineering from the University of Minnesota and a B.S. in Chemical Engineering with High Distinction from Worcester Polytechnic Institute (WPI).
Bruce Beutel, Ph.D. is a Venture Partner of the Qiming U.S. Healthcare Fund. Previously, he served asChief Operating Officer and Chief Business & Strategy Officer at Dewpoint Therapeutics, Chief Business Officer at SQZ Biotechnologies, and as Executive Director, Business Development at Merck.
He currently serves as an Independent Director on the Boards of GRO Biosciences and Boston Immune Technologies & Therapeutics.
Bruce received his B.A. in Biology from the University of Chicago and his Ph.D. in Molecular Biology from the University of Wisconsin-Madison in the lab of M. Thomas Record, Jr.
Steve is the Managing Director of Healthcare Ventures at Ziff Capital Partners and Chair of the Board of Spark Therapeutics. Previously he served as CEO of the University of Miami and the University of Miami Health System as well as the CEO of The Children’s Hospital of Philadelphia (CHOP). Steve’s medical training was in pediatrics and gastroenterology. In addition to Spark, he serves on the boards of Mead Johnson Nutritionals and Weight Watchers.
Mark is a managing partner of the Qiming U.S. Healthcare Fund. Previously, he served as chief operating officer of UCB Pharma, CEO of PDL BioPharma, CEO of Signature BioScience and COO of Boehringer Mannheim Therapeutics. He serves on the boards of FivePrime Therapeutics, Dermira Inc., and Aimmune Therapeutics. He received his M.B.A. from Harvard Business School.
Phil is a venture partner at Third Rock Ventures and has served as Chief Medical Officer of Goldfinch Bio, co-founder of Fulcrum Therapeutics, co-founder and Chief Medical Officer of Voyager Therapeutics, Chief Medical Officer of Bluebird Bio, co-founder of Edimer, among other startup roles. He served as Chairman and CEO of Interleukin Genetics. He earned his medical degree at the Yale School of Medicine.
Richard Murray has served as Chief Executive Officer and President of Jounce Therapeutics, along with sitting on the Board of Directors, since July, 2014. He brings to Jounce more than two decades of biologics R&D leadership and experience moving product candidates through development to commercialization for both startup biotechnology and large pharmaceutical companies. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.
Joseph Italiano, Ph.D. is an associate professor at Harvard Medical School, where he leads his own lab focused on platelet production. He is also assistant professor in the Department of Surgery at Children’s Hospital Boston. Dr. Italiano earned his Ph.D. in cell biology from Florida State University. He is a co-founder of PlateletBio and Chairman of the company’s scientific advisory board.
Co-founder and Chair
Uma Lakshmipathy has over 17 years of experience in cell biology, stem cells and translational research. She is currently the Director of R&D at Thermo Fisher Scientific, driving key initiatives and new product development in stem cells, cell & gene therapy. Her work is focused on development of clinical-grade reagents and processes, viral and non-viral methods of cell modification and, analytical platforms for comprehensive cell therapy product characterization. Uma was previously at University of Minnesota Stem Cell Institute involved in non-viral gene transfer and ex vivo repair of stem cells for monogenic disorders. She has a doctoral degree in Molecular Biophysics from the Center for Cellular and Molecular Biology in India, postdoctoral experience in DNA double strand break repair from University of Minnesota Medical School and, has authored several scientific publications, books and patents.
Teresa (Teri) Foy is an immunologist with 25 years of experience in the biotechnology and pharmaceutical industry developing novel therapeutics in the areas of inflammation and immuno-oncology. Teri is currently Corporate Vice President and Head of Celgene’s Immuno-Oncology (IO) and Cellular Therapy (CT) Thematic Center of Excellence (TCoE) in Seattle. Celgene’s IO CT TCoE is focused on development and translation of Celgene’s early IO and Cellular Therapy pipeline from discovery through human proof of concept. Teri joined Celgene in 2014 and established Celgene’s Seattle site. Early in her career Teri held scientific leadership positions at Corixa Corp. and Glaxo Smith Kline, both in Seattle WA. Teri served as the Chief Scientific Officer at VLST, developing therapeutics for autoimmune and inflammatory diseases. She holds a Ph.D. in Immunology from the University of Iowa and completed a post-doctoral fellowship in Immunology at Dartmouth Medical School. Teri has an extensive publication record and holds close to a dozen patents for novel immune compositions.
Bruce Zetter, Ph.D., is professor of cancer biology and surgery at Harvard Medical School, researcher at Boston Children’s Hospital and discoverer of the world’s first angiogenesis inhibitor.
Dr. Ploegh is a biochemist by training and one of the world’s foremost experts on the immune system. He is known for his analysis of the pathways involved in antigen presentation by products of the Major Histocompatibility Complex (MHC). PlateletBio is developing a next-generation pipeline of cell therapies for autoimmune diseases and Dr. Ploegh’s expertise will accelerate the company’s path to delivering therapeutic benefit to patients.
Dr. Ploegh has spent more than 10 years at the MIT's Whitehead Institute for Biomedical Research and is currently at Boston Children’s Hospital in their Program in Cellular and Molecular Medicine. Ploegh is a correspondent of the Royal Dutch Academy of Sciences, a member of EMBO, a fellow of the American Academy of Arts and Sciences, and a member of the National Academy of Sciences.